News Archive

Date: 08/01/2013
Experts call for more support for tumor biomarker tests; fixing a vicious cycle will lead to tests that better predict treatment successWritten by Nicole Fawcett
Date: 07/24/2013
A new, high-risk prostate cancer clinic is available at the University of Michigan Comprehensive Cancer Center for men with fast-growing prostate cancer.
Date: 07/23/2013
OncoMed Pharmaceuticals, a company started at the University of Michigan in 2004, raised $82 million in an initial public offering.
Date: 07/08/2013
Certain chronic conditions for which urology practices are well-suited, and in some cases, better equipped, to carry out medical home functions compared to their primary care counterparts, according to a new study led by researchers from the University of Michigan.
Date: 06/26/2013
University of Michigan Comprehensive Cancer Center researchers believe killing stem cells is key to improving cancer treatment.
Date: 06/25/2013
Despite being unlikely to benefit, more patients with low risk prostate cancer receiving advanced procedures according to new University of Michigan study in JAMA.
Date: 06/19/2013
Dr. Weizer is an associate professor of urology at the U-M Medical School. His appointment is effective June 17, 2013.
Date: 06/13/2013
Researchers at the University of Michigan Comprehensive Cancer Center looked at 169 cancer clinical practice guidelines for lung, breast, prostate and colorectal cancers and found that none of the guidelines fully met standards set in 2011 by the Institute of Medicine.
Date: 06/12/2013
Novel abnormalities in the FGFR gene, called FGFR fusions, were identified in a spectrum of cancers, and preliminary results with cancer cells harboring FGFR fusions suggested that some patients with these cancers may benefit from treatment with FGFR inhibitor drugs, University of Michigan Comprehensive Cancer Center researchers are reporting.
Date: 06/10/2013
Novel abnormalities in the FGFR gene, called FGFR fusions, were identified in a spectrum of cancers, and preliminary results with cancer cells harboring FGFR fusions suggested that some patients with these cancers may benefit from treatment with FGFR inhibitor drugs, University of Michigan Comprehensive Cancer Center researchers are reporting.

Pages